Thus, targeting CD200R1 for breaking CD200/CD200R1 immune tolerance in cancer presents an opportunity to target multiple immune cell populations in addition to T cells in the tumor (17), such as myeloid and NK cells, which has been shown to be a promising approach in preclinical research (18, 19). This evidence concerns the gene CD200 and cancer.